CD BioGlyco is dedicated to helping clients explore the development of glycan biological functions. As a leading biotechnology company in the field of glycomics, we comprehensively dissect molecular interactions and biological functions of glycans through a wide range of biological analysis services. The cell-based O-glycan array is composed of a series of Glyco-engineered Cell lines (HEK293 cells), which express homogeneous and personalized O-glycans in cellular expression and are used for validation of conformational relationships.
Cell surface O-glycans have structural diversity and complexity. The binding of cell surface O-glycosylation capacity with ligands provides a means for studying the molecular recognition mechanism. Meanwhile, CD BioGlyco provides more comprehensive and systematic engineering development services based on cell-based O-glycan arrays displaying glycocell bio-interrogation. We provide services ranging from cell-based O-glycan array construction to biosynthesis genetic regulation metabolic analysis.
High-purity O-glycans are key to building arrays. At the glycan display platform, we provide a series of HEK293 cells genetically engineered to express O-glycans with specific structures e.g. O-GalNAc, O-Fuc, O-Man, O-Glc, O-Xyl, O-Gal and O-GlcNAc. Our researchers have a richer experience with array expansion to ensure fast array construction and validation.
Our researchers provide fast and accurate selection services to help clients pick out glycan-binding proteins (GBP) or glycan-binding reagents. Based on the information (known / partially known / unknown), we provide corresponding services. Our talent team has a rich background in glycobiology and rich experience in industry services to grasp every key node.
Combined with a large number of isogenic cells and cell-based O-glycan arrays, we provide binding-specific detection services by high-throughput flow cytometry. We provide surface binding, membrane localization, density, or aggregation assessment services by immunohistochemistry. Furthermore, we provide live cells to immobilized O-glycan recognition services.
Fig.1 Schematic diagram of cell-based O-glycan array screen and analysis (CD BioGlyco)
Paper Title: Installation of O-glycan sulfation capacities in human HEK293 cells for display of sulfated mucins
Technology: RNA sequencing, Knockin, Knockout, Flow cytometry
Journal: Journal of Biological Chemistry
Published: 2022
IF: 5.485
Results: In this paper, a cell-based glycan array was extended by a sialylation-competent HEK293 cell line. Endogenous glycan branching and sialylation capacity were eliminated by targeted knockout of the sulfotransferase gene in combination with knockout genes to provide a simplified substrate introduction of sulfotransferases. In addition, analysis of lectin binding specificity using engineered cell libraries indicated binding to the 3-O-sulfo-core1 O-glycan. Importantly, a cell-based platform was used to display and produce glycoconjugates of sulfated O-glycans. This strategy is generalizable to other sulfotransferases.
Fig.2 Intact mass analysis of the Lys-C-purified mucin1 TR O-glycodomain. (Sun, et al., 2022)
CD BioGlyco has a professional Glycan Display Platform to provide clients with Cell-based Glycan Display Array services. We are committed to being your best partner in the field of glycobiology. To learn more information about cell-based O-glycan arrays, please feel free to contact us.
References